Literature DB >> 15778353

Direct cross-priming by th lymphocytes generates memory cytotoxic T cell responses.

Richard Kennedy1, Anita H Undale, William C Kieper, Matthew S Block, Larry R Pease, Esteban Celis.   

Abstract

Under optimal Ag stimulation, CTL become functional effector and memory T cells. Professional APCs (pAPC) are considered essential for the activation of CTL, due to their unique capacity to provide costimulation and present exogenous Ags through MHC class I molecules. In this study, we report a novel means by which Th lymphocytes acquire and present MHC class I determinants to naive CTL. Although previous studies have looked at T cell Ag presentation to activated T cells, this study presents the first example of Ag presentation by Th cells to naive CTL. We report that activated Th cells can function as effective pAPC for CTL. Our results show that: 1) In addition to acquisition of cell surface molecules, including MHC class I/peptide complexes, from pAPC, Th cells can acquire and present MHC class I-binding peptides through TCR-MHC class II interactions with pAPC; 2) the acquired Ag can be functionally presented to CTL; and 3) Ag presentation by Th cells induces naive CTL to proliferate and preferentially differentiate into cells that phenotypically and functionally resemble central memory T cells. These findings suggest a novel role of Th cells as pAPC for the development of memory immune responses.

Mesh:

Substances:

Year:  2005        PMID: 15778353     DOI: 10.4049/jimmunol.174.7.3967

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses.

Authors:  Siguo Hao; Yongqing Liu; Jinying Yuan; Xueshu Zhang; Tianpei He; Xiaochu Wu; Yangdou Wei; Deming Sun; Jim Xiang
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

2.  CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.

Authors:  Hui Huang; Siguo Hao; Fang Li; Zhenmin Ye; Junbao Yang; Jim Xiang
Journal:  Immunology       Date:  2007-02       Impact factor: 7.397

3.  The composition of immune cells serves as a predictor of adaptive immunity in a cohort of 50- to 74-year-old adults.

Authors:  Richard B Kennedy; Whitney L Simon; Michael J Gibson; Krista M Goergen; Diane E Grill; Ann L Oberg; Gregory A Poland
Journal:  Immunology       Date:  2016-05-17       Impact factor: 7.397

4.  Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.

Authors:  Zhaoting Meng; Yadong Wang; Guanzhong Zhang; Yuehua Ke; Yanfeng Yan; Liangliang Wu; Qianrong Huang; Gang Zeng; Yu Wang; Han Ying; Shunchang Jiao
Journal:  J Immunother       Date:  2011-09       Impact factor: 4.456

5.  The identification of HLA class II-restricted T cell epitopes to vaccinia virus membrane proteins.

Authors:  Richard B Kennedy; Gregory A Poland
Journal:  Virology       Date:  2010-10-18       Impact factor: 3.616

Review 6.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

Review 7.  Receptor-mediated T cell absorption of antigen presenting cell-derived molecules.

Authors:  Inkyu Hwang; DaLim Ki
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

8.  Assessing in vitro and in vivo Trogocytosis By Murine CD4+ T cells.

Authors:  Jim Reed; Scott A Wetzel
Journal:  Bio Protoc       Date:  2020-05-05

9.  T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.

Authors:  Sang-Eun Lee; A-Ri Shin; Hyun-Jung Sohn; Hyun-Il Cho; Tai-Gyu Kim
Journal:  Cancer Res Treat       Date:  2020-02-14       Impact factor: 4.679

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.